378 results on '"Arnott, I"'
Search Results
2. DOP17 Tofacitinib versus Vedolizumab Among Bio-naïve Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison
3. P745 Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort
4. P509 Surgery and biologic prescription rates for Crohn's disease in Lothian, Scotland; an updated population-based cohort study
5. P557 Analysis of colectomy rates and advanced therapy prescribing for ulcerative colitis in Lothian; Scotland an updated population based cohort study
6. Establishing key performance indicators for inflammatory bowel disease in the UK
7. DOP072 Achieving biochemical remission with adalimumab therapy using therapeutic drug monitoring: Results of a large prospective Crohn’s disease cohort
8. Inflammatory bowel disease patient-reported quality assessment should drive service improvement: A national survey of UK IBD units and patients
9. P333 Changing patterns of biological therapy use with the introduction of biosimilars in inflammatory bowel disease
10. P125 Rapid increase in pan-treatment refractory Crohnʼs disease after transition to adult services: a regional cohort study
11. P579 Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohns’s disease
12. Predicting outcome in acute severe ulcerative colitis: comparison of the Travis and Ho scores using UK IBD audit data
13. Systematic review with meta-analysis: endoscopic balloon dilatation for Crohnʼs disease strictures
14. PTU-084 Long term outcomes after transition to adult services in paediatric-onset inflammatory bowel disease patients treated with anti-tnf
15. OC-001 Endoscopic balloon dilatation for crohn’s disease strictures: a systematic review and meta-analysis
16. Diverticular disease in Scotland: 2000–2010
17. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients
18. Letter: faecal calprotectin and lactoferrin – accurate biomarkers in post-operative Crohnʼs disease – authorsʼ reply: Letter: biologic therapies are effective for prevention of post-operative Crohnʼs disease recurrence – authorsʼ reply
19. Systematic review: the use of thiopurines or anti-TNF in post-operative Crohnʼs disease maintenance – progress and prospects
20. Letter: acute severe ulcerative colitis - should all patients be treated equally?
21. Detailed assessment of NOD2/CARD15 exonic variation in inflammatory bowel disease in Scotland: implications for disease pathogenesis
22. DOP72 Perianal Crohn’s Disease in the biologic era: A population-based cohort study
23. P129 IBD care in the UK: A comprehensive, novel service assessment with feedback from 10,222 patients and 166 NHS organisations to inform a vision for quality improvement
24. P330 Long-term outcomes following a switch from originator adalimumab to the biosimilar SB5 (Imraldi) in IBD
25. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe?
26. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis
27. Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit
28. Diverticular disease emergency surgery in NHS Scotland 2000-2010: F15
29. OC-166 Predictive factors of disease relapse following thiopurine withdrawal for sustained clinical remission of IBD
30. OC-165 No increase in surgical complication in patients treated with rescue therapy for acute severe ulcerative colitis: data from the UK IBD audit
31. OC-050 Inpatient paediatric UC care in the UK in 2011 is characterised by increasing rates of rescue therapy and stool cultures but low use of pucai scores
32. First european Ethical Code on the use of reproductive medicine: O-132
33. Temporal Trends in Surgical Resection Rates and Biologic Prescribing in Crohn’s Disease: A Population-based Cohort Study
34. P575 Real-world effectiveness and safety of ustekinumab for the treatment of refractory Crohn’s disease: The Scottish ustekinumab cohort
35. DOP11 Normalisation of faecal calprotectin within 12 months of diagnosis is associated with a reduced risk of disease progression in Crohn’s disease
36. Efficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004–2008)
37. Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis
38. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up
39. Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis
40. The use of adalimumab in the management of refractory Crohnʼs disease
41. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease
42. Multiple liver lesions in a smoker
43. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis
44. Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)
45. Lack of association of the pregnane X receptor (PXR/NR1I2) gene with inflammatory bowel disease: parallel allelic association study and gene wide haplotype analysis
46. DLG5 variants and susceptibility to inflammatory bowel disease in the Scottish population: Authors’ reply
47. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort
48. DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish population
49. Toll-like receptor 4 gene in IBD: further evidence for genetic heterogeneity in Europe
50. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohnʼs disease are associated with disease severity but not NOD2/CARD15 mutations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.